Categories
Change Password!
Reset Password!
While Sprifermin injection was effective in patients with
knee osteoarthritis it also not showed any significant adverse effects.
The use of
intra-articular injection of sprifermin (a recombinant human fibroblast growth factor 18)
was found safe in patients with knee osteoarthritis (KOA), a study in Arthritis Research &
Therapy eludicated.
Ni Zeng et al. performed this meta-analysis which compared the
structural progression and clinical symptom outcomes along with adverse events
of sprifermin in case of KOA. A systematic literature search found 8 studies
associated with long-term outcomes between sprifermin and placebo injections in
KOA patients were considered. RevMan5.3 was used to perform meta-analysis.
As compared to placebo, the patients using sprifermin
injection experienced considerably less improvement of Western Ontario and McMaster Universities Osteoarthritis Index
scores. Also, sprifermin , intra-articular injection helped to improve the
cartilage thickness and volume in key spheroid
part of the stifle joint
in KOA patients. A significant difference in terms of variations in the
morphology of cartilage surface of the medial tibiofemoral and patellofemoral
joint was observed in sprifermin and placebo users. No noteworthy
difference was observed in the risk of treatment-emergent adverse events
between sprifermin and the placebo users.
Sprifermin can be considered as a possible
disease-modifying osteoarthritis therapy but after the validation of further
studies to determining its safety and efficacy in KOA patients.
Arthritis Research & Therapy
Efficacy and safety of sprifermin injection for knee osteoarthritis treatment: a meta-analysis
Ni Zeng et al.
Comments (0)